Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
University of California, San Francisco | San Francisco, California | United States | about 1 month ago
, including genomics, transcriptomics, proteomics, and metabolomics. Develop and apply advanced bioinformatics pipelines and tools for multi-omics data integration and analysis. Identify biomarkers and
-
70% part-time basis,at the Institute of Biosciences and Bioresources - Research Division Naples. Where to apply Website https://selezionionline.cnr.it/ Requirements Research FieldBiological
-
of advancing biomarker discovery in multiple sclerosis and related neuroinflammatory conditions. Key Responsibilities 1. Research Operations & Laboratory Management Contribute to the development and
-
biophysical network models of The Virtual Brain (TVB) type, we aim to mechanistically explain patient heterogeneity and identify prognostic biomarkers. This is a high-impact, interdisciplinary project bridging
-
for CANDIDATES to apply for a “Jiménez Díaz” 2026 Predoctoral Research Grant, published by the Conchita Rábago de Jiménez Díaz Foundation (https://www.fundacionconchitarabago.net). The candidate will join the
-
biologists. The appointee will work as an independent investigator tacking musculoskeletal disorders with advanced biotechnology and biomaterials to provide solutions such as biomarkers for precision clinical
-
compounds and dose-response. Identification of biomarkers, as well as proteomic and genomic signatures associated with drug response relevant to clinical trials. Preparing scientific manuscripts and
-
execution of studies for the identification and validation of biomarkers associated with Alzheimer’s disease. Processing and analysis of biological samples (cerebrospinal fluid, plasma, brain tissue, etc
-
set to advance their careers in this vital field. ACHILLES is supported by experts in hemato-oncology and experimental therapeutics, integrating research on biomarkers and therapeutic targets
-
glycosylation disorders and translate our findings into improved therapies and diagnostic biomarkers. Using patient‑derived materials, we apply cutting‑edge metabolomics and (glyco)proteomics to dissect disease